Jade Biosciences (NASDAQ:JBIO) Sees Unusually-High Trading Volume – Should You Buy?

Jade Biosciences, Inc. (NASDAQ:JBIO) shares saw strong trading volume on Wednesday . 376,730 shares traded hands during mid-day trading, an increase of 13% from the previous session’s volume of 332,190 shares.The stock last traded at $14.4850 and had previously closed at $14.05.

Analysts Set New Price Targets

A number of research firms have issued reports on JBIO. Stifel Nicolaus set a $40.00 price target on Jade Biosciences in a research note on Friday, March 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. William Blair upgraded Jade Biosciences to a “strong-buy” rating in a report on Monday, March 9th. Lifesci Capital raised Jade Biosciences to a “strong-buy” rating in a research report on Friday, March 6th. Finally, Guggenheim upped their price target on Jade Biosciences from $17.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Jade Biosciences currently has an average rating of “Moderate Buy” and an average price target of $29.50.

Jade Biosciences Price Performance

The firm has a market capitalization of $776.73 million, a PE ratio of -3.33 and a beta of 1.03. The firm’s fifty day moving average is $14.62 and its two-hundred day moving average is $12.69.

Jade Biosciences (NASDAQ:JBIO) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.34.

Institutional Trading of Jade Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc purchased a new position in Jade Biosciences in the second quarter worth $29,000. Russell Investments Group Ltd. purchased a new stake in shares of Jade Biosciences during the 2nd quarter valued at $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Jade Biosciences during the 2nd quarter valued at $32,000. Ameritas Investment Partners Inc. bought a new stake in shares of Jade Biosciences during the 2nd quarter worth $33,000. Finally, California State Teachers Retirement System raised its stake in shares of Jade Biosciences by 40.3% during the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after purchasing an additional 819 shares during the period.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.